Literature DB >> 24342948

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.

N M Anderson1, I Harrold1, M R Mansour2, T Sanda3, M McKeown4, N Nagykary1, J E Bradner4, G Lan Zhang5, A T Look6, H Feng1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24342948      PMCID： PMC4013222          DOI： 10.1038/leu.2013.377

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Authors:  Matthew S Davids; Anthony Letai
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

Review 3.  Launching the T-cell-lineage developmental programme.

Authors:  Ellen V Rothenberg; Jonathan E Moore; Mary A Yui
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

4.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 5.  BH3 mimetics to improve cancer therapy; mechanisms and examples.

Authors:  Lin Zhang; Lihua Ming; Jian Yu
Journal:  Drug Resist Updat       Date:  2007-10-24       Impact factor: 18.500

6.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Authors:  Jinghui Zhang; Li Ding; Linda Holmfeldt; Gang Wu; Sue L Heatley; Debbie Payne-Turner; John Easton; Xiang Chen; Jianmin Wang; Michael Rusch; Charles Lu; Shann-Ching Chen; Lei Wei; J Racquel Collins-Underwood; Jing Ma; Kathryn G Roberts; Stanley B Pounds; Anatoly Ulyanov; Jared Becksfort; Pankaj Gupta; Robert Huether; Richard W Kriwacki; Matthew Parker; Daniel J McGoldrick; David Zhao; Daniel Alford; Stephen Espy; Kiran Chand Bobba; Guangchun Song; Deqing Pei; Cheng Cheng; Stefan Roberts; Michael I Barbato; Dario Campana; Elaine Coustan-Smith; Sheila A Shurtleff; Susana C Raimondi; Maria Kleppe; Jan Cools; Kristin A Shimano; Michelle L Hermiston; Sergei Doulatov; Kolja Eppert; Elisa Laurenti; Faiyaz Notta; John E Dick; Giuseppe Basso; Stephen P Hunger; Mignon L Loh; Meenakshi Devidas; Brent Wood; Stuart Winter; Kimberley P Dunsmore; Robert S Fulton; Lucinda L Fulton; Xin Hong; Christopher C Harris; David J Dooling; Kerri Ochoa; Kimberly J Johnson; John C Obenauer; William E Evans; Ching-Hon Pui; Clayton W Naeve; Timothy J Ley; Elaine R Mardis; Richard K Wilson; James R Downing; Charles G Mullighan
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

7.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Authors:  John M Goldberg; Lewis B Silverman; Donna E Levy; Virginia Kimball Dalton; Richard D Gelber; Leslie Lehmann; Harvey J Cohen; Stephen E Sallan; Barbara L Asselin
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

Review 8.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

9.  ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

Authors:  Cassandra J Vandenberg; Suzanne Cory
Journal:  Blood       Date:  2013-01-22       Impact factor: 22.113

10.  ETV6 mutations in early immature human T cell leukemias.

Authors:  Pieter Van Vlierberghe; Alberto Ambesi-Impiombato; Arianne Perez-Garcia; J Erika Haydu; Isaura Rigo; Michael Hadler; Valeria Tosello; Giusy Della Gatta; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik; Selina M Luger; Jacob M Rowe; Montserrat Rue; Adolfo A Ferrando
Journal:  J Exp Med       Date:  2011-12-12       Impact factor: 14.307
View more
  19 in total

Review 1.  BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.

Authors:  Christopher J Gibson; Matthew S Davids
Journal:  Clin Cancer Res       Date:  2015-11-15       Impact factor: 12.531

Review 2.  Pathways and mechanisms of venetoclax resistance.

Authors:  Prithviraj Bose; Varsha Gandhi; Marina Konopleva
Journal:  Leuk Lymphoma       Date:  2017-01-31

3.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

4.  Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.

Authors:  S Peirs; V Frismantas; F Matthijssens; W Van Loocke; T Pieters; N Vandamme; B Lintermans; M P Dobay; G Berx; B Poppe; S Goossens; B C Bornhauser; J-P Bourquin; P Van Vlierberghe
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

Review 5.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

6.  Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.

Authors:  Koshi Akahane; Zhaodong Li; Julia Etchin; Alla Berezovskaya; Evisa Gjini; Craig E Masse; Wenyan Miao; Jennifer Rocnik; Rosana Kapeller; Jeremy R Greenwood; Hong Tiv; Takaomi Sanda; David M Weinstock; A Thomas Look
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

7.  The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL.

Authors:  Alessandra Di Grande; Sofie Peirs; Paul D Donovan; Maaike Van Trimpont; Julie Morscio; Beatrice Lintermans; Lindy Reunes; Niels Vandamme; Steven Goossens; Hien Anh Nguyen; Arnon Lavie; Richard B Lock; Jochen H M Prehn; Pieter Van Vlierberghe; Triona Ní Chonghaile
Journal:  Blood Adv       Date:  2021-04-13

8.  Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.

Authors:  Triona Ni Chonghaile; Justine E Roderick; Cian Glenfield; Jeremy Ryan; Stephen E Sallan; Lewis B Silverman; Mignon L Loh; Stephen P Hunger; Brent Wood; Daniel J DeAngelo; Richard Stone; Marian Harris; Alejandro Gutierrez; Michelle A Kelliher; Anthony Letai
Journal:  Cancer Discov       Date:  2014-07-03       Impact factor: 39.397

9.  Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.

Authors:  Bing Z Carter; Po Yee Mak; Hong Mu; Hongsheng Zhou; Duncan H Mak; Wendy Schober; Joel D Leverson; Bin Zhang; Ravi Bhatia; Xuelin Huang; Jorge Cortes; Hagop Kantarjian; Marina Konopleva; Michael Andreeff
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

10.  Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

Authors:  Benoit M Cyrenne; Julia M Lewis; Jason G Weed; Kacie R Carlson; Fatima N Mirza; Francine M Foss; Michael Girardi
Journal:  Blood       Date:  2017-10-02       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.